ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 425,60
0,76%
Dow Jones
43 729,34
0,00%
DAX
19 362,52
1,71%
Brent Oil
75,175
-0,38%
Bitcoin
75 765,70
-0,18%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. (MM) (NBS) Cours

(MM)

(MM) (NBS)

Nationwide Building Society
2,25
0,00
(0,00%)
Fermé 08 Novembre 10:00PM
Retardé de 15 minutes
0,00
0,00
(0,00%)
Après les heures de négociation: -
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
2,25
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
2,25
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

NBS Dernières nouvelles

Plus de nouvelles

NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company

NEW YORK, May 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based individualized medicine therapies...

29 Mai 2015
GlobeNewswire Inc.

NeoStem Prices $25,000,000 Public Offering of Common Stock

NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today the pricing of an underwritten public offering of 12,500,000 shares of common...

28 Mai 2015
GlobeNewswire Inc.

NeoStem Announces Proposed Public Offering of Common Stock

NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today that it is commencing an underwritten public offering of its common stock...

27 Mai 2015
GlobeNewswire Inc.

NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for ...

NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies...

26 Mai 2015
GlobeNewswire Inc.

Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem

NEW YORK, May 21, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) announced Thursday that it will receive one of the largest research grants of its kind to support its pioneering treatment...

21 Mai 2015
GlobeNewswire Inc.

NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update

NEW YORK, May 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies...

05 Mai 2015
GlobeNewswire Inc.

NeoStem to Present at Multiple May and June Conferences

NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the Company's...

04 Mai 2015
GlobeNewswire Inc.

NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

NEW YORK, April 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the...

29 Avril 2015
GlobeNewswire Inc.

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma PR Newswire LAKE FOREST, Calif., April 29, 2015 LAKE FOREST, Calif., April 29, 2015 /PRNewswire/ -- Cryoport, Inc...

29 Avril 2015
PR Newswire (US)

NeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From the European Medicines Agency

NEW YORK, April 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the...

27 Avril 2015
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CELUCelularity Inc
US$ 3,063
(111,24%)
46,67M
WBUYWeBuy Global Ltd
US$ 0,2371
(109,08%)
1,49B
MTENMingteng International Corporation Inc
US$ 6,73
(49,56%)
477,83k
NMHINatures Miracle Holding Inc
US$ 0,1425
(47,06%)
420,5M
APPApplovin Corporation
US$ 246,57
(46,29%)
18,62M
APPSDigital Turbine Inc
US$ 1,79
(-44,75%)
25,08M
XELAExela Technologies Inc
US$ 1,1801
(-40,40%)
2,6M
ALTOAlto Ingredients Inc
US$ 1,205
(-37,89%)
7,65M
SPPLSIMPPLE Ltd
US$ 0,8801
(-35,29%)
3,17M
XRAYDENTSPLY SIRONA Inc
US$ 17,25
(-28,07%)
30,26M
WBUYWeBuy Global Ltd
US$ 0,2371
(109,08%)
1,48B
NMHINatures Miracle Holding Inc
US$ 0,1425
(47,06%)
420,39M
XTIAXTI Aerospace Inc
US$ 0,0494
(-2,18%)
352,3M
ELABElevai Labs Inc
US$ 0,017916
(0,65%)
304,75M
NVDANVIDIA Corporation
US$ 148,88
(2,25%)
203,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
NBS
NeoStem, Inc.
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés